GI CANCERS

SHR-1701, a PD-L1 and TGF-ß targeting agent, reduced chemotherapy-induced myelosuppression in patients with HER2-negative gastric/GEJ adenocarcinoma.

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in Chinese patients with advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma.

In patients with advanced ESCC treated with first-line tislelizumab plus chemotherapy, deeper responses and longer time to maximum response were linked to improved overall survival.

The combination of everolimus plus lanreotide showed an improvement in progression-free survival and an acceptable safety profile vs everolimus monotherapy in gastroenteropancreatic neuroendocrine tumors.

Here are the most anticipated abstracts to keep an eye on going into the 2025 ASCO Gastrointestinal Cancers Symposium.

LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for pancreatic cancer treatment.

The approval of this combination is supported by data from the phase 3 CodeBreaK 300 study.

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.

Ghassan K. Abou-Alfa, MD, discusses the findings and key takeaways from the SUMMIT trial, which evaluated the use of neratinib for the treatment of patients with fibrolamellar carcinoma.

Ghassan K. Abou-Alfa, MD, discusses neratinib and its use as a monotherapy and in combination with immune checkpoint inhibitors and/or mTOR inhibitors in the SUMMIT trial.

2024 saw the establishment of docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil as the preferred regimen for patients with localized adenocarcinoma.

Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with lutetium 177 dotatate for treating well-differentiated somatostatin receptor–-positive neuroendocrine tumors.

The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or metastatic gastric and gastroesophageal junction adenocarcinoma.

During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.

The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting its 100% clinical complete response rate in a phase 2 study.

Josep M. Llovet, MD, PhD, describes the phase 3 LEAP-012 clinical study, including its methods, design, and enrollment criteria.

Zanidatamab is now a category 2A treatment for HER2-positive biliary tract cancer in the NCCN guidelines, following its FDA approval.

With this approval, zenocutuzumab is the first FDA-approved therapy for patients with NRG1 fusion tumors.

Enrollment in cohort 5 of the phase 1/2 GOBLET study will resume after the Data Safety Monitoring Board’s safety review.

The PANOVA-3 trial demonstrated a significant 2-month overall survival improvement when adding tumor treating fields to gemcitabine and nab-paclitaxel for patients with locally advanced pancreatic adenocarcinoma.

Enrollment has been completed for the phase 1b/2 ASIST study that is evaluating BXQ-350 in combination with standard-of-care treatments in patients with newly diagnosed metastatic colorectal cancer.

The FDA approved the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test as a companion diagnostic to assess HER2+ status in patients with BTC.

Shubham Pant, MD, MBBS, discussed the use of zanidatamab and the HERIZON-BTC-01 trial in HER2-positive biliary tract cancer treatment.

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.

Yanghee Woo, MD, discusses the details and lasting impact of the CROSS trial in the treatment of gastroesophageal junction and esophageal cancers.

Yanghee Woo, MD, provides an overview of the CROSS trial which focused on treating patients with gastroesophageal junction cancers.

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration of response in patients with advanced biliary tract cancer.

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or refractory microsatellite-stable metastatic colorectal cancer.

Mark A. Lewis, MD, discusses dostarlimab-gxly and how experts can best counsel patients with locally advanced mismatch repair-deficient rectal cancer about the potential for long-term disease control with this agent.